This statistic displays the average time between a medicine gaining marketing authorization and patient access in European countries as of January 5, 2024. According to the data, Germany had an average time of 126 days between authorization and access for medicines, compared to nearly 918 days in Romania.
Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country
(in days)
Patient access is defined for most countries as the point at which the product gains access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme.
* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not take into account France's system of temporary authorization for some products, which means this time will be higher than in reality.
***MHRA’s Early Access to Medicines Scheme provides access prior to marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
IQVIA, & EFPIA. (June 25, 2024). Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country (in days) [Graph]. In Statista. Retrieved December 21, 2024, from https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, und EFPIA. "Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country (in days)." Chart. June 25, 2024. Statista. Accessed December 21, 2024. https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, EFPIA. (2024). Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country (in days). Statista. Statista Inc.. Accessed: December 21, 2024. https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA, and EFPIA. "Average Time between Marketing Authorization and Patient Access for Medicines in Europe as of 2024, by Country (in Days)." Statista, Statista Inc., 25 Jun 2024, https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/
IQVIA & EFPIA, Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country (in days) Statista, https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/ (last visited December 21, 2024)
Average time between marketing authorization and patient access for medicines in Europe as of 2024, by country (in days) [Graph], IQVIA, & EFPIA, June 25, 2024. [Online]. Available: https://www.statista.com/statistics/1011197/europe-time-between-medicine-authorization-and-access/
